____________________________________ FORM 10-Q ____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_________to_________ Commission File Number: 001-40034 _________________ ...

Exhibit 99.1 GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI- 0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) and over two-thirds enrollment completed for the overall trial Cash runway e ...

Exhibit 99.1 Cash runway expected to fund operations through Q3 2025 LA JOLLA, CA, May 15, 2025 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the quarter ended March 31, 2025 and provided a corporate update. "We continue to make very encouraging progress with our ongoing Phase 2a trial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40556 THE GLIMPSE GROUP, INC. (Exact name of registrant as specified in its charter) Nevada 81-2958271 (State or other jurisdic ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Lantern Pharma Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | Delaware | 001-39318 | 46-3973463 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Empl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Date of Report (date of earliest event reported): May 15, 2025 Adial Pharmaceuticals, Inc. (Exact name of registrant as specified in charter) (State or other jurisdiction of incorporation) Delaware 001-38323 82-3074668 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Commission File Number) (IRS Employer Identification No.) 4870 Sadler Road, Ste 300 Glen Allen, VA 23060 (Address of principa ...

Exhibit 99.1 The Glimpse Group Reports Q3 Fiscal Year 2025 Financial Results Reaf irm Revenues and Second Consecutive Quarter of Positive Cash Flow NEW YORK, NY, May 15, 2025 - The Glimpse Group, Inc. ("Glimpse") (NASDAQ: VRAR; FSE: 9DR), a diversified Immersive Technology platform company providing enterprise-focused Virtual Reality ("VR"), Augmented Reality ("AR") and Spatial Computing software and services, provided financial results for its third quarter fiscal year 2025, ended March 31, 2025 ("Q3 FY '2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organization) 7683 SE 27 Street, Suite 481 Mercer I ...

Revenue Growth - Total revenue increased by $501,148, or 212%, from $236,677 for the three months ended March 31, 2024, to $737,825 for the same period in 2025, driven by a 38% increase in locations using services[99]. - Cloud video surveillance subscriptions increased by 79%, remote guarding increased by 164%, hardware sales increased by 241%, and installation labor sales increased by 397% compared to the same period in 2024[99]. Expenses - Cost of goods sold increased by $154,242, or 61%, from $253,232 for the three months ended March 31, 2024, to $407,473 for the same period in 2025[103]. - General and administrative expenses increased by 114% for the three months ended March 31, 2025, primarily due to a one-time bonus of $323,000 paid to employees[107]. - Research and development expenses increased by 71% for the three months ended March 31, 2025, with payroll increasing by $237,000 due to a one-time bonus[108]. Net Loss - Net loss for the three months ended March 31, 2025, was $2.5 million, compared to a net loss of $1.7 million for the same period in 2024, representing a 46% increase in loss[111]. Cash Position - Cash and cash equivalents at the end of the period were $6.845 million for the three months ended March 31, 2025, compared to $(1.028) million for the same period in 2024[115]. - Net cash provided by financing activities was $9.4 million for the three months ended March 31, 2025, compared to approximately $0 for the same period in 2024[120]. - As of March 31, 2025, the company had approximately $6.9 million in cash and $6.8 million in working capital, expecting current cash to fund operations through at least Q1 2026[126]. Future Outlook - The company anticipates entering additional markets in 2025 and 2026, focusing on expanding its customer base in the property management space[89]. - The company expects to incur additional losses for the foreseeable future as it continues to expand and develop new products and services[125]. - The company has an accumulated deficit of approximately $43.4 million as of March 31, 2025, and expects to continue incurring operating losses and negative cash flows for the foreseeable future[128]. - The Series 2 Purchase Agreement and Equity Purchase Agreement may provide necessary funding for the next 12 months, but their execution is subject to conditions beyond the company's control[127]. Financial Management - The company has a planning and budgeting process to monitor operating cash requirements, including capital expenditures, general and administrative costs, and public company operating costs[129]. - Contractual obligations primarily relate to operating lease obligations, capital lease obligations, and insurance obligations, which are generally terminable after a notice period[130]. - The company does not have any long-term debt or significant long-term liabilities as of the reporting period[131]. Regulatory Status - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to take advantage of certain reporting exemptions[133]. - The company has elected to use an extended transition period for complying with new accounting standards, which may affect the comparability of its financial statements[134]. - The company is not required to provide certain disclosures related to executive compensation due to its status as an emerging growth company[138]. - The company evaluates its accounting estimates and assumptions on an ongoing basis, which may impact reported amounts of assets, liabilities, revenue, and expenses[140].

Exhibit 99.1 Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash. (May 15, 2025) – Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company") reports financial results for the three months ended March 31, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and busi ...